Mercer Global Advisors Inc. ADV Purchases 139,173 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Mercer Global Advisors Inc. ADV increased its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 1,391.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 149,176 shares of the company’s stock after acquiring an additional 139,173 shares during the quarter. Mercer Global Advisors Inc. ADV owned about 0.07% of Hims & Hers Health worth $3,012,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Nisa Investment Advisors LLC increased its position in shares of Hims & Hers Health by 679.2% during the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after purchasing an additional 1,603 shares in the last quarter. Quest Partners LLC boosted its position in shares of Hims & Hers Health by 5,944.1% in the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock worth $72,000 after purchasing an additional 3,507 shares in the last quarter. Van ECK Associates Corp purchased a new position in Hims & Hers Health during the 2nd quarter worth $111,000. Daiwa Securities Group Inc. acquired a new position in Hims & Hers Health during the 2nd quarter valued at about $142,000. Finally, DekaBank Deutsche Girozentrale purchased a new stake in Hims & Hers Health in the second quarter valued at about $143,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Insider Activity

In related news, CEO Andrew Dudum sold 188,888 shares of Hims & Hers Health stock in a transaction on Wednesday, July 3rd. The shares were sold at an average price of $20.75, for a total value of $3,919,426.00. Following the sale, the chief executive officer now owns 33,502 shares of the company’s stock, valued at approximately $695,166.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CEO Andrew Dudum sold 188,888 shares of the firm’s stock in a transaction dated Wednesday, July 3rd. The shares were sold at an average price of $20.75, for a total value of $3,919,426.00. Following the transaction, the chief executive officer now directly owns 33,502 shares of the company’s stock, valued at approximately $695,166.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Soleil Boughton sold 2,339 shares of the business’s stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $16.50, for a total value of $38,593.50. Following the sale, the insider now owns 176,952 shares of the company’s stock, valued at $2,919,708. The disclosure for this sale can be found here. Insiders sold 684,601 shares of company stock worth $11,967,928 over the last three months. 17.71% of the stock is currently owned by corporate insiders.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS opened at $16.30 on Monday. The company has a market capitalization of $3.50 billion, a PE ratio of -1,630.00 and a beta of 1.05. The company’s fifty day moving average price is $17.35 and its 200 day moving average price is $17.07. Hims & Hers Health, Inc. has a 1 year low of $5.65 and a 1 year high of $25.74.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.04 by $0.02. The business had revenue of $315.65 million for the quarter, compared to analyst estimates of $302.43 million. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The company’s revenue for the quarter was up 51.8% on a year-over-year basis. During the same period in the prior year, the company posted ($0.03) EPS. On average, equities analysts expect that Hims & Hers Health, Inc. will post 0.22 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on HIMS shares. Deutsche Bank Aktiengesellschaft boosted their price target on Hims & Hers Health from $16.00 to $23.00 and gave the stock a “hold” rating in a research note on Wednesday, August 7th. Piper Sandler restated a “neutral” rating and set a $18.00 price target on shares of Hims & Hers Health in a research note on Tuesday, August 6th. Jefferies Financial Group lifted their price objective on shares of Hims & Hers Health from $14.00 to $23.00 and gave the stock a “hold” rating in a research note on Thursday, June 27th. TD Cowen upped their target price on Hims & Hers Health from $15.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, July 11th. Finally, Needham & Company LLC assumed coverage on Hims & Hers Health in a research note on Thursday, August 22nd. They issued a “buy” rating and a $24.00 target price for the company. Eight investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, Hims & Hers Health has a consensus rating of “Moderate Buy” and an average price target of $19.86.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.